Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer.
Explore this paper's citation graph
Summary
This study showed STMs to be good predictors of tumor response and in metastatic cancer they might be useful to optimize the timing of radiological re-evaluation in the palliative setting.
- Type
- article
- Published
- 2003-10-01
- Cited by
- 17
- References
- 21
- OpenAlex
- https://openalex.org/W2976006
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25044244
Keywords
Medicine, Concordance, Internal medicine, Chemotherapy, Oncology
References
- Mucin gene expression in ovarian cancers.
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
- Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
- 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
- Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125
- Large sample standard errors of kappa and weighted kappa.
- Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours
- Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.
- CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.
- Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres.
- Comparison of Preoperative Serum CA19‐9 Levels with Results of Diagnostic Imaging Modalities in Patients Undergoing Laparotomy for Suspected Pancreatic or Gallbladder Disease
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
- A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
- The measurement of observer agreement for categorical data.
- Reporting results of cancer treatment
- Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Cited by
- Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
- Biomarkers for the lung cancer diagnosis and their advances in proteomics.
- Recommendations For Clinical Use Of Tumor Markers In Lung Cancer
- Safety of pregnancy following breast cancer
- Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.
- Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis Using Serum Tumor Markers: An Observational Cohort Study
- Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas
- Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?
- Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer.
- Diagnostic relevance of circulating biomarkers in patients with lung cancer
- The role of thymidine kinase in cancer diseases.
- KARCINOM PLU)A - KLINI^KE IMPLIKACIJE LUNG CANCER - CLINICAL IMPLICATIONS
- CARCINOGENICITY OF CHROMIUM AMONG STEEL WORKERS: A COMPARATIVE CROSS SECTIONAL STUDY
- Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.
- Evaluation of Serum Hormones and Biochemical Tumor Markers among Breast Cancer Patients in the South-South Region, Nigeria
- Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer.
- PREPORUKE ZA PRIMENU TUMORSKIH MARKERA KOD KANCERA PLU)A RECOMMENDATIONS FOR CLINICAL USE OF TUMOR MARKERS IN LUNG CANCER
Related papers
- TS-1 による術後補助療法中に発症しWeekly Docetaxel 療法により著効をみた胃癌腹膜播種の1 例
- The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel.
- Docetaxel (Taxotere): preclinical and general clinical information.
- Weekly docetaxel in the treatment of metastatic breast cancer
- Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
- Docetaxel for metastatic breast cancer: two consecutive phase II trials.
- Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
- A phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
- Abstract P6-12-08: Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/− Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)